Innovassynth Technologies (India) Limited has filed its quarterly compliance certificate with BSE Limited for the quarter ended March 31, 2026, fulfilling its regulatory obligations under SEBI regulations.

Regulatory Compliance Submission

The company submitted the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as required by Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The submission was made on April 13, 2026, and signed by Company Secretary Sameer Pakhali.

Certificate Details from Registrar

Satellite Corporate Services Private Limited, serving as the company's Registrar and Transfer Agent, issued the compliance certificate on April 06, 2026. The certificate confirms proper handling of physical share certificates received for dematerialization of the company's equity shares.

The Registrar certified two key compliance points:

• The securities comprised in the certificates have been listed on the Stock Exchanges
• The certificates have been properly verified, mutilated, cancelled, and the depository name has been substituted in records as the registered owner

Company Information

Innovassynth technologies operates from its registered office at Old Mumbai-Pune Road, Khopoli, and maintains its corporate office at TCG International Biotech Park in Pune. The company, formerly known as Innovassynth Investments Limited, trades under scrip code 533315 on BSE.

This quarterly filing demonstrates the company's commitment to maintaining regulatory compliance and transparency in its share transfer and dematerialization processes.

Innovassynth Technologies (India) Limited's board of directors has approved a rights issue proposal to raise funds up to ₹70 crores through equity shares. The board meeting held on March 27, 2026, concluded with the approval of issuing equity shares of face value ₹10 each to eligible shareholders.

Board Meeting Outcome

The board meeting, which commenced at 4:30 p.m. and concluded at 4:50 p.m., addressed the fund-raising proposal and approved the rights issue for an aggregate amount not exceeding ₹70 crores, subject to receiving applicable regulatory and statutory approvals. The company formally notified BSE Limited about the board meeting outcome pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Rights Issue Committee Formation

The board constituted a dedicated Rights Issue Committee with authorization to determine crucial aspects of the offering. The committee will decide on terms and conditions including the final issue size, rights entitlement ratio, issue price, record date, timing of the rights issue, approval of draft letter of offer, allotment of shares and other related matters.

Regulatory Compliance and Documentation

The company's communication to BSE was signed by Sameer Pakhali, Company Secretary (ACS 55746), and digitally authenticated on March 27, 2026. The filing included detailed annexure as required under Regulation 30 of the Listing Regulations read with SEBI circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Company Information

Innovassynth Technologies (India) Limited operates from its registered office at Old Mumbai–Pune Road, Khopoli – 410 203, and corporate office at TCG International Biotech Park, 2nd Floor, Genesis Square, Hinjewadi Phase – II, Pune – 411 057. The company trades on BSE under scrip code 533315 with CIN: L67120MH2008PLC178923. The rights issue represents a significant capital mobilization initiative for the company's growth plans.